3-aminobenzamide has been researched along with Parkinson Disease in 2 studies
Parkinson Disease: A progressive, degenerative neurologic disease characterized by a TREMOR that is maximal at rest, retropulsion (i.e. a tendency to fall backwards), rigidity, stooped posture, slowness of voluntary movements, and a masklike facial expression. Pathologic features include loss of melanin containing neurons in the substantia nigra and other pigmented nuclei of the brainstem. LEWY BODIES are present in the substantia nigra and locus coeruleus but may also be found in a related condition (LEWY BODY DISEASE, DIFFUSE) characterized by dementia in combination with varying degrees of parkinsonism. (Adams et al., Principles of Neurology, 6th ed, p1059, pp1067-75)
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Wu, XL | 1 |
| Wang, P | 1 |
| Liu, YH | 1 |
| Xue, YX | 1 |
| Chiba-Falek, O | 1 |
| Kowalak, JA | 1 |
| Smulson, ME | 1 |
| Nussbaum, RL | 1 |
2 other studies available for 3-aminobenzamide and Parkinson Disease
| Article | Year |
|---|---|
Effects of poly (ADP-ribose) polymerase inhibitor 3-aminobenzamide on blood-brain barrier and dopaminergic neurons of rats with lipopolysaccharide-induced Parkinson's disease.
Topics: Animals; Benzamides; Blood-Brain Barrier; Claudin-5; Dopaminergic Neurons; Interleukin-1beta; Lipopo | 2014 |
Regulation of alpha-synuclein expression by poly (ADP ribose) polymerase-1 (PARP-1) binding to the NACP-Rep1 polymorphic site upstream of the SNCA gene.
Topics: Alleles; alpha-Synuclein; Base Sequence; Benzamides; Binding Sites; Cell Line; DNA; Enzyme Inhibitor | 2005 |